Johnson & Johnson
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joaquin Duato
- Full Time Employees
- 140,800
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- One Johnson & Johnson Plaza New Brunswick NJ United States 08933
- IPO Date
- Sep 25, 1944
- CIK
- 0000200406
- Website
- jnj.com
- Similar Companies
- Business
- Johnson & Johnson is a global healthcare company engaged primarily in the research, development, manufacture, and sale of a broad range of pharmaceutical, medical device, and consumer health products. The company operates segments including Pharmaceuticals, Medical Devices, and Consumer Health, offering products such as prescription medicines for immunology, oncology, neuroscience, infectious diseases; orthopedic and surgical devices; and branded consumer healthcare products like Band-Aid and Listerine. Founded in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson serves customers worldwide across multiple markets. Recent major changes include Johnson & Johnson's 2025 acquisition of neurological drug maker Intra-Cellular Therapies for approximately $14.6 billion, expanding its neuroscience portfolio. In November 2025, J&J also announced the acquisition of Halda Therapeutics for $3.05 billion to bolster its oncology pipeline with innovations targeting metastatic castration-resistant prostate cancer. The company launched new cancer therapies Vykt, Tecvayli, and Talvey targeting multiple myeloma, generating $1.3 billion in sales in the first half of 2025. Furthermore, J&J is advancing drug candidates such as nipocalimab (Imaavy) for immune-mediated disorders and Caplyta for bipolar depression. The company also plans to divest its consumer health segment, signaling a strategic shift to focus more intensively on pharmaceuticals and medical devices. Johnson & Johnson continues to pursue regulatory approvals and expand indications for key drugs including SIMPONI, STELARA, TREMFYA, and Caplyta. It projects peak sales of several pipeline candidates at approximately $5 billion each. The firm remains heavily invested in research and development across immunology, oncology, neuroscience, and autoimmune diseases, leveraging innovative technologies including adenovirus vector and mRNA platforms. Johnson & Johnson reported a 6.8% sales increase to $24 billion in Q3 2025, reflecting operational growth driven by its pharmaceutical segment. This combination of advanced product portfolios, strategic acquisitions, and selective divestitures positions Johnson & Johnson as a leading global medical and pharmaceutical company focused on delivering innovative therapeutic solutions worldwide. The company's broad geographic operations span North America, Europe, Asia-Pacific, and emerging markets, catering to diverse healthcare needs across prescription drugs, medical devices, and consumer health products.
Company News
3 Dependable Dividend Stocks for a $250,000 Passive Income Strategy
2,899 Johnson & Johnson $JNJ Shares Sold by Franklin Parlapiano Turner & Welch LLC
Roth IRA vs. Taxable Account: How Much of $13,467 in Dividends Would You Keep?
Johnson & Johnson $JNJ Stock Bought by BOCHK Asset Management Ltd
Smith+Nephew cuts outlook, confirms failed merger talks with J&J's orthopaedics unit
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
Jim Cramer Likes This Industrial Stock: ‘It's Come Down A Great Deal'
Johnson & Johnson $JNJ Stake Boosted by Investment Partners LTD.
Johnson & Johnson $JNJ Stock Purchased by Hollow Brook Wealth Management LLC
5,146 Johnson & Johnson $JNJ Shares Sold by Heritage Investors Management Corp
The Best Dividend Stocks to Buy With $5,000 in November
2 Safe S&P 500 Healthcare Dividend Stocks Boomers Can Buy and Hold Forever
3 Best Dividend Stocks for a $100,000 Passive Income Strategy
33,097 Johnson & Johnson $JNJ Shares Bought by International Assets Investment Management LLC
Gray Private Wealth LLC Acquires New Position in Johnson & Johnson $JNJ
4 Blue-Chip Dividend Stocks That Kept Raising Payouts Through 2008 and 2020
Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
Suze Orman Says You Don’t Have to Buy Every Market Dip. Here’s Why
Roth IRA vs. Taxable Account: How Much of $17,985 in Blue-Chip Dividends Would You Keep?